Annotation Detail

Information
Associated Genes
NRG1
Associated Variants
NRG1 NRG1 FUSIONS
NRG1 NRG1 FUSIONS
Associated Disease
pancreatic adenocarcinoma
Source Database
CIViC Evidence
Description
In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in two patients with NRG1-rearranged tumors that had proved resistant to standard treatment. One patient (30) was treated with afatinib monotherapy and showed improvement at 7 weeks, followed by progression at 3 months after necessary dose reduction.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6273
Gene URL
https://civic.genome.wustl.edu/links/genes/2593
Variant URL
https://civic.genome.wustl.edu/links/variants/2286
Rating
4
Evidence Type
Predictive
Disease
Pancreatic Adenocarcinoma
Evidence Direction
Supports
Drug
Afatinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
29802158
Drugs
Drug NameSensitivitySupported
AfatinibSensitivitytrue